The ongoing legal battle over mifepristone, the first drug used in medication abortion, reached a critical milestone when a federal appeals court issued a ruling on one of the most contested aspects of the medication’s access: mailing. For patients, clinicians, and advocates, the decision clarified (and complicated) the future of abortion pill access across the U.S.
What the Appeals Court Ruled on Mailing Mifepristone
The 5th U.S. Circuit Court of Appeals, in a split August 2023 decision, issued a specific ruling on the FDA’s 2021 policy change that allowed mifepristone to be mailed directly to patients and prescribed via telehealth without a required in-person clinic visit.
The court found that the FDA’s decision to lift the in-person dispensing mandate and allow mail delivery was likely “arbitrary and capricious,” meaning it did not follow proper administrative procedures or rely on sufficient scientific evidence to justify the change.
Importantly, the appeals court did not ban mifepristone entirely. Its ruling targeted only the 2021 mail and telehealth provisions, leaving other FDA approval rules for the drug intact.
Key Details of the 5th Circuit Decision
To understand the full scope of the ruling on mailing mifepristone, break down the court’s core findings:
- Ruled the 2021 FDA policy allowing mifepristone to be mailed without an in-person doctor visit is likely unlawful
- Upheld the FDA’s 2016 rule changes, including extending mifepristone use to 10 weeks of gestation and allowing nurse practitioners and physician assistants to prescribe the drug
- Rejected the lower district court’s nationwide ban on mifepristone, narrowing the scope of relief to only the plaintiff states (Texas, Louisiana, Mississippi) in the initial lawsuit
- Stayed its own ruling pending appeal, meaning mailing of mifepristone remained legal nationwide while the case moved to the Supreme Court
Why Mailing Mifepristone Became a Legal Flashpoint
Mifepristone has been FDA-approved for medication abortion since 2000, but for decades, the agency required it to be dispensed in person at a clinic or doctor’s office, with no mail delivery allowed.
During the COVID-19 pandemic, the FDA temporarily lifted the in-person dispensing requirement, allowing mailing and telehealth prescribing to reduce virus exposure risks. In 2021, the agency made that policy permanent, citing years of safety data showing mifepristone is safe and effective when used without in-person visits.
Anti-abortion groups sued the FDA in 2022, arguing the 2021 policy change was illegal and posed safety risks. The lawsuit eventually reached the 5th Circuit appeals court, which focused heavily on the mailing and telehealth provisions.
Status of the Ruling Today
It is important to note that the appeals court’s ruling on mailing mifepristone is not currently in effect. The U.S. Supreme Court stayed the 5th Circuit’s decision shortly after it was issued, preserving the FDA’s 2021 mail and telehealth rules for mifepristone nationwide while the case is fully litigated.
As of now, patients can still access mifepristone via mail and telehealth in all 50 states where medication abortion is legal.
What Comes Next for Mifepristone Access
The appeals court ruling on mailing mifepristone is just one step in a longer legal battle that will likely end at the Supreme Court. For now, access to the drug via mail remains protected, but the 5th Circuit’s decision sets a precedent that could be used to challenge other FDA reproductive health policies.
Patients and providers should monitor updates from the FDA and legal advocacy groups to stay informed about changes to mifepristone access in their area.
Comments are closed, but trackbacks and pingbacks are open.